Beam Q2 net loss $102.3M; cash $1.2B; BEAM-302 17 patients dosed; BEAM-101 enrollment complete

Beam Therapeutics Inc.

2025-Q2 EPS reported -$2.23 revenue$15,936,000

Net loss of $102.3M ($1.00/share) vs $91.1M loss ($1.11/share) in Q2 2024; R&D expense rose to $101.8M.
Cash, cash equivalents and marketable securities $1.2B as of June 30, 2025; runway into 2028.
BEAM-302 Phase 1/2: 17 patients dosed; expanded dose exploration underway; Part B enrollment initiated; data expected early 2026.
BEAM-101 BEACON trial: 30 SCD patients dosed (adults + first adolescent); updated data expected by end of 2025.
FDA granted orphan drug designation for BEAM-101 and BEAM-302, and RMAT designation for BEAM-302.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.